D
David C. Montefiori
Researcher at Duke University
Publications - 995
Citations - 79717
David C. Montefiori is an academic researcher from Duke University. The author has contributed to research in topics: Antibody & Virus. The author has an hindex of 129, co-authored 920 publications receiving 70049 citations. Previous affiliations of David C. Montefiori include Emory University & University of California, Davis.
Papers
More filters
Posted ContentDOI
SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys
Kevin O. Saunders,Esther J. Lee,Robert Parks,David R. Martinez,Dapeng Li,Haiyan Chen,Robert J. Edwards,Sophie M. C. Gobeil,Maggie Barr,Katayoun Mansouri,S. Munir Alam,Laura L. Sutherland,Fangping Cai,Aja Sanzone,Madison Berry,Kartik Manne,Anyway B. Kapingidza,Mihai L. Azoitei,Longping V. Tse,Trevor Scobey,Rachel L. Spreng,R. Wes Rountree,C. Todd DeMarco,Thomas N. Denny,Christopher W. Woods,Elizabeth Petzold,Thomas H. Oguin,Gregory D. Sempowski,Matthew Gagne,Daniel C. Douek,Mark A. Tomai,Christopher B. Fox,Robert A. Seder,Kevin Wiehe,Drew Weissman,Norbert Pardi,Priyamvada Acharya,Hanne Leth Andersen,Mark G. Lewis,Ian N. Moore,David C. Montefiori,Ralph S. Baric,Barton F. Haynes +42 more
TL;DR: This article showed that immunization of macaques with a multimeric SARS-CoV-2 receptor binding domain (RBD) nanoparticle adjuvanted with 3M-052-Alum elicited cross-neutralizing antibody responses against SARS, CoV-1, SARS CoVs-2, batCoVs and the UK B.1.7 SARS co-virus mutant virus.
Journal ArticleDOI
Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies.
Pranay Bharadwaj,Cassidy Riekofski,Shu Lin,Michael S. Seaman,David A. Garber,David C. Montefiori,Marcella Sarzotti-Kelsoe,Margaret E. Ackerman,Joshua A. Weiner +8 more
TL;DR: Qualification of a set of ADA assays available to the scientific community as pre-clinical and clinical trials of broadly HIV-neutralizing antibodies proceed are reported, and a framework that is easily adapted as new drug products are advanced in the clinic is reported.
Journal ArticleDOI
mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice
Zekun Mu,Kevin Wiehe,Kevin O. Saunders,Rory Henderson,Derek W. Cain,Robert Parks,Diana Martik,Katayoun Mansouri,Robert Edwards,Amanda Newman,Xiaozhi Lu,Shi-Mao Xia,Amanda Eaton,Mattia Bonsignori,David C. Montefiori,Qifeng Han,Sravani Venkatayogi,Tyler D. Evangelous,Yunfei Wang,Wes Rountree,Bette T. Korber,Kshitij Wagh,Ying K. Tam,Christopher Barbosa,S. Munir Alam,Wilton B. Williams,Ming Tian,Frederick W. Alt,Norbert Pardi,Drew Weissman,Barton F. Haynes +30 more
TL;DR: The success of nucleoside-modified mRNAs in lipid nanoparticles (mRNA-LNP) as COVID-19 vaccines heralded a new era of vaccine development as mentioned in this paper .
Journal ArticleDOI
Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein.
Russell Vassell,Yong He,Prasad Vennakalanti,Antu K. Dey,Min Zhuang,Min Zhuang,Wei Wang,Yide Sun,Zohar Biron-Sorek,Indresh K. Srivastava,Celia C. LaBranche,David C. Montefiori,Susan W. Barnett,Carol D. Weiss +13 more
TL;DR: This work describes the antigenicity and immunogenicity of a panel of oligomeric gp41 immunogens designed to model a fusion-intermediate conformation of Env in order to enhance MPER exposure in a relevant conformation and informs the design of future MPER immunogens and immunization protocols.
Journal ArticleDOI
Effect of complement consumption by cobra venom factor on the course of primary infection with simian immunodeficiency virus in rhesus monkeys
Jörn E. Schmitz,Michelle A. Lifton,Keith A. Reimann,David C. Montefiori,Ling Shen,Paul Racz,Klara Tenner-Racz,Markus Ollert,Meryl A. Forman,Rebecca Gelman,Carl-Wilhelm Vogel,Norman L. Letvin +11 more
TL;DR: The results suggest that complement proteins may participate in immune defense mechanisms that decrease virus replication following the initial burst of intense viremia during primary SIVmac infection.